Repaglinide

Category: pharmacological

Aliases: Prandin

Pharmacological Mechanism

Meglitinide — closes pancreatic β-cell K-ATP channels (same target as sulfonylureas, distinct binding site) → insulin release. Short half-life supports pre-prandial dosing for post-prandial glucose control. Hepatic CYP2C8 + CYP3A4 substrate.

Half-Life (t½)

PO: 1h

Dosing Guidelines

• PO: Typical 1mg (Range: 0.5 - 16 mg)

Target Organ Systems

• endocrine
• digestive